Processa Pharmaceuticals, Inc.(PCSA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Processa Pharmaceuticals, Inc. (PCSA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PCSA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of PCSA by reported 13-F value include Connective Capital Management, Stonepine Capital Management, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. PCSA trades on the Nasdaq exchange and files with the SEC under CIK 1533743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Processa Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

$-3.3M

PCSA key financials by period

Processa Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 201610-K$5.0K$-1.9M—
FY 201510-K$113.4K$-3.4M—
FY 201410-K$107.2K$-4.5M—
FY 201310-K$520.2K$-6.5M—
FY 201210-K$192.1K$-2.4M—

Institutions holding PCSA

Institutional investors reporting a position in Processa Pharmaceuticals, Inc. on SEC Form 13F.
InstitutionSharesValueReported
Connective Capital Management85,274$163.7K2026-06-30
Stonepine Capital Management55,000$105.6K2026-06-30
GEODE CAPITAL MANAGEMENT22,090$42.4K2026-06-30
CITADEL ADVISORS21,306$40.9K2026-06-30
StoneX Group11,437$29.6K2026-06-30
XTX Topco Ltd13,292$25.5K2026-06-30
JANE STREET GROUP13,264$25.5K2026-06-30
VANGUARD CAPITAL MANAGEMENT12,729$24.4K2026-06-30
VANGUARD FIDUCIARY10,857$20.8K2026-06-30
UBS Group AG7,794$15.0K2026-06-30
SEC EDGAR: CIK 1533743 →
PCSA

Processa Pharmaceuticals, Inc.

PCSA
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-3.27M

EPS (Diluted)

Q2 2026
EDGAR

$-1.19

Top Institutional Holders

as of Q2 2026
$498.3K total
Connective Capital Management, LLC
$163.7K+20.6%
Stonepine Capital Management, LLC
$105.6K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$42.4K-11.3%
CITADEL ADVISORS LLC
$40.9KNew
StoneX Group Inc.
$29.6KNew
XTX Topco Ltd
$25.5KNew
JANE STREET GROUP, LLC
$25.5KNew
VANGUARD CAPITAL MANAGEMENT LLC
$24.4K0.0%
VANGUARD FIDUCIARY TRUST CO
$20.8K0.0%
UBS Group AG
$15.0K+207.9%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…